Glycyrrhizin

药械追踪No.1 / 国内首款安加维生物类似药！迈威生物迈卫健获批近日，迈威生物宣布，迈卫健获中国药监局批准上市，用于治疗不可手术切除或者手术切除可能导致严重功能障碍的骨巨细胞瘤，包括成人和骨骼发育成熟（定义为至少 1 处成熟长骨且体重≥45 kg）的青少年患者，成为中国首款获批上市的安加维（地舒单抗注射液，120mg）生物类似药。地舒单抗是由安进公司开发的一种新型RANKL抑制剂，是RANKL的全人化单克隆IgG2抗体；基于2020年与安进达成的战略合作，百济神州获得地舒单抗在中国的商业化及开发权利。->点击阅读原文，解锁完整双语新闻No.2 /传奇生物CARVYKTI在美获批R/R MM二线适应证传奇生物近日宣布，已批准CAR-T疗法CARVYKTI用于既往接受过至少一线治疗（包括蛋白酶体抑制剂和免疫调节剂）的复发/难治性（R/R）多发性骨髓瘤（MM）成人患者。这是全球首个且目前唯一获批用于MM二线治疗的B细胞成熟抗原（BCMA）靶向的细胞疗法。->点击阅读原文，解锁完整双语新闻No.3 / 驯鹿生物CAR-T治疗重症肌无力获FDA批准新药临床近日，驯鹿生物自主研发的全人源靶向BCMA嵌合抗原受体自体T细胞注射液（伊基奥仑赛注射液，研发代号CT103A）新药临床试验申请获FDA批准，拟用于治疗难治性全身型重症肌无力（gMG），该产品此项适应证中国IND于今年1月份已获NMPA批准。2023年6月30日，伊基奥仑赛已获中国国家药监局批准上市，用于治疗复发难治多发性骨髓瘤成人患者，既往经过至少三线治疗后进展->点击阅读原文，解锁完整双语新闻No.4 /益普生兰瑞肽在华获批胃肠胰神经内分泌瘤适应证2024年4月3日，益普生近日宣布醋酸兰瑞肽缓释注射液（预充式）于3月29日获国家药监局正式批准新适应证，用于不可切除、高分化或中分化、局部晚期或转移性胃肠胰神经内分泌瘤的成人患者，以改善无进展生存期；用于类癌综合征成人患者：接受本品治疗时可减少短效生长抑素类似物应急治疗的频率。索马杜林是全球唯一获批可进行深部皮下自我注射的生长抑素类似物（SSA）类药物，2019年12月，该药在中国获批用于治疗肢端肥大症，并被纳入国家医保目录。->点击阅读原文，解锁完整双语新闻企业动态No.1 / 卫材与华润医药达成复方甘草酸苷片合作近日，卫材与华润医药商业及华润三九在上海签订复方甘草酸苷片（商品名：美能）合作协议。三方将积极拓展、强强联合，在传统医疗、创新项目、患者管理、互联网医疗健康等领域开展深度合作，提升三方在医药领域的服务价值。二十世纪40年代，日本药企米诺发源制药株式会社就从甘草中成功提取了甘草酸苷，并与甘氨酸和半胱氨酸（蛋氨酸）共同组成复方制剂——复方甘草酸苷（SNMC）。->点击阅读原文，解锁完整双语新闻全球医疗情报领导者解锁隐藏在数据中的商业潜力 关于 G B I”自从2002年成立以来，GBI始终以技术为驱动，为药企、器械及行业相关服务商提供贯穿生命周期的全球药品市场竞争数据、全球行业资讯、HCPs洞察、全国医疗器械数据等商业信息与洞察，助力企业在进行战略布局和决策时，脱颖而出。历经20愈年的深耕细作GBI已成为95%以上跨国药企、国内头部药企、咨询与投资机构等医疗圈灯塔用户值得信赖的长期合作伙伴。联系我们投稿 | 发稿 | 媒体合作▶ sylvia.hua@generalbiologic.com数据库 | 咨询服务 | 资讯追踪▶ 点击左下“阅读原文”完成表单填写点击阅读原文，解锁完整双语新闻

It is known that large amounts of licorice cause high blood pressure. A new study now shows that even small amounts of licorice raise blood pressure. The individuals who react most strongly also show signs of strain on the heart. It is known that large amounts of liquorice cause high blood pressure. A study by researchers at Linköping University, Sweden, now shows that even small amounts of liquorice raise blood pressure. The individuals who react most strongly also show signs of strain on the heart. Liquorice is produced from the root of plants of the Glycyrrhiza species and has long been used as a herbal remedy and flavouring. However, it is known that eating liquorice can also raise blood pressure. This is mainly due to a substance called glycyrrhizic acid that affects the body's fluid balance through effects on an enzyme in the kidney. High blood pressure, in turn, increases the risk of cardiovascular disease. Both the European Union and the World Health Organization have concluded that 100 mg of glycyrrhizic acid per day is probably safe to eat for most individuals. But some people eat more liquorice than that. The Swedish Food Agency has estimated that 5 per cent of Swedes have an intake higher than this level. In the current study, published in The American Journal of Clinical Nutrition, researchers at Linköping University wanted to test whether the limit stated as likely safe actually is so or not. It is not easy to know how much glycyrrhizic acid is in the liquorice you eat, as its concentration in different liquorice products varies greatly. This variation may depend on factors such as origin, storage conditions and liquorice root species. In addition, the amount of glycyrrhizic acid is not indicated on many products. The Linköping University study is the first to have carefully measured the amount of glycyrrhizic acid in the liquorice that was tested, while being randomised and having a control group. In the study, 28 women and men aged 18-30 were instructed to eat liquorice, or a control product that did not contain any liquorice, over two periods of time. The control product instead contained salmiak, which gives salty liquorice its flavour. The liquorice weighed 3.3 grammes and contained 100 mg of glycyrrhizic acid, that is, the amount indicated as likely safe for most people to eat daily. Participants were randomly assigned to eat either liquorice or the control product for two weeks, take a break for two weeks, and then eat the other variety for two weeks. This enabled the researchers to compare the effect of both varieties in the same person. The study participants were asked to measure their blood pressure at home every day. At the end of each intake period, the researchers measured levels of various hormones, salt balance, and heart workload. "In the study, we found that a daily intake of liquorice containing 100 mg glycyrrhizic acid raised blood pressure in young healthy people. This hasn't previously been shown for such small amounts of liquorice," says Peder af Geijerstam, doctoral student at the Department of Health, Medicine and Caring Sciences at Linköping University, general practitioner, and lead author of the study. When the participants ate liquorice, their blood pressure increased by an average of 3.1 mmHg. The researchers also measured two hormones that are affected by liquorice and that regulate fluid balance: renin and aldosterone. The levels of both of these decreased when eating liquorice. The quarter of the study participants who were most sensitive, based on their levels of the hormones renin and aldosterone decreasing the most after eating liquorice, also gained slightly in weight, most likely due to an increased amount of fluid in the body. This group also had elevated levels of a protein that the heart secretes more of when it needs to work harder to pump around the blood in the body, N-terminal pro-brain natriuretic peptide (NT-proBNP). This suggests increased fluid volume and heart workload in the individuals most sensitive to the effects of liquorice. "Our results give reason to be more cautious when it comes to recommendations and labelling for food containing liquorice," says Fredrik Nyström, professor at the same department, who was responsible for the study. The study was funded with support from, among others, The Strategic Research Network in Circulation and Metabolism (LiU-CircM) at Linköping University, The National Research School in General Practice at Umeå University, King Gustaf V and Queen Victoria Freemason Foundation and Region Östergötland.